OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care

Share Article

Cleveland Clinic’s cancer center is at the forefront of clinical, translational and basic cancer research.

News Image
“We look forward to sharing breakthroughs in research and cancer care spurred by Cleveland Clinic,” said Mike Hennessy Jr., president of Intellisphere Oncology and Healthcare Specialty Group, MJH.

OncLive® today announced it is teaming up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to provide breaking news and information about the hospital’s pioneering research and care for cancer patients.

Editorial and marketing groups within OncLive, which provides oncologists resources and information they need to deliver the best care for their patients, will focus on many cancer-related programs and initiatives at Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Its cancer center provides world-class care to patients with cancer and is at the forefront of new and emerging clinical, translational and basic cancer research.

More than 250 highly skilled doctors, nurses and other healthcare professionals provide advanced cancer care to more than 14,000 patients with cancer each year at Cleveland Clinic’s cancer center. Clinical trials and internationally known cancer research efforts ensure that patients have access to the latest advances in cancer treatment. A range of support programs are available to help patients navigate the changes and challenges associated with cancer.

The Clinic’s Lerner Research Institute, which conducts research in a wide variety of diseases, includes the Department of Cancer Biology, where scientists are identifying the molecular mechanisms involved in the development and progression of cancer by studying tumor suppressor genes, DNA damage and repair, and cell signaling, among other areas. A team from this department recently discovered that abiraterone, an FDA-approved steroid synthesis inhibitor used to treat metastatic prostate cancer, converts to a more active metabolite called D4A in patients with prostate cancer, and that the metabolite is more effective at killing metastatic prostate cancer cells than the drug itself.

“We look forward to sharing breakthroughs in research and cancer care spurred by Cleveland Clinic,” said Mike Hennessy Jr., president of Intellisphere Oncology and Healthcare Specialty Group, part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. (MJH), family of businesses. “There should be no shortage of important news coming from this organization.”

“This collaboration with OncLive is opportune because it will allow us to share our new discoveries, with the hope of fostering collaboration, spurring additional discovery and benefiting patients,” said Dr. Brian Bolwell, chairman of Cleveland Clinic Cancer Institute.

About OncLive
OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News and Contemporary Oncology. OncLive offers oncology professionals resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc., family of businesses, based in Plainsboro, N.J. 

MJH is also the parent company of CURE Media Group, which includes CURE® magazine, the largest consumer publication in the U.S. focused entirely on cancer, and curetoday.com, the magazine’s online resource. CURE reaches patients, cancer centers and advocacy groups, and combines science and humanity to make cancer understandable. For more information, visit http://www.onclive.com/, http://www.curetoday.com or http://www.mjhassoc.com/.

Media Contact
For OncLive: Becky Taylor, 609-240-6886, becky(at)btaylorpa(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Becky Taylor
OncLive
+1 609-240-6886
Email >
@OncLive
since: 05/2009
Follow >
Visit website